{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:49:30Z","timestamp":1790952570113,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Bone metastasis most commonly occurs in castration-resistant prostate cancer (CRPC). The TRPV6 calcium channel is absent in healthy prostate tissue, but its expression increases considerably during cancer progression. We hypothesized that cancer cells induce TRPV6 expression de novo to directly benefit from tightly regulated calcium intake <jats:italic>via<\/jats:italic> TRPV6 while providing cancer cells with a selective advantage for metastasis in the calcium-abundant niche, such as bone. Using a cohort of prostate cancer tissue biopsies from patients with a clinical history of at least 10 years after biopsy, we report that TRPV6 expression directly correlates with CRPC tumor aggressiveness and increased risk of metastasis development. The TRPV6 channel is involved in the acquisition of both mesenchymal and invasive phenotypes through increased phosphorylation of CaMK2 followed by the translocation of the transcription factor NF-\u03baB to the nucleus and the expression of EMT markers, MMPs, and transcription factors such as Twist, Snail, and Slug. Moreover, TRPV6 expression was accompanied by increased formation of CXCR4\/TRPV6 complexes. In vivo, mice bearing <jats:italic>trpv6<\/jats:italic>\n            <jats:sup>\n              <jats:italic>+\/+<\/jats:italic>\n            <\/jats:sup> tumors presented increased metastasis, notably bone metastasis, whereas <jats:italic>trpv6<\/jats:italic>\n            <jats:sup>\n              <jats:italic>\u2212\/\u2212<\/jats:italic>\n            <\/jats:sup> mice developed no metastasis. Targeting TRPV6 with a monoclonal antibody resulted in a significant reduction in the metastatic burden and an increase in overall survival. When AMD3100, a selective inhibitor of the CXCR4 receptor, was combined with AMD3100, a synergistic effect on the suppression of metastasis development was achieved. Thus, the suppression of CRPC metastasis to bone can be achieved <jats:italic>via<\/jats:italic> simultaneous targeting of TRPV6\/CXCR4, demonstrating that combined therapy is a proof-of-concept approach in vivo.<\/jats:p>","DOI":"10.1038\/s41392-025-02376-8","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T23:02:28Z","timestamp":1757026948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting TRPV6\/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone"],"prefix":"10.1038","volume":"10","author":[{"given":"Cl\u00e9ment","family":"Cordier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Haustrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Desruelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Casel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Slimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Soret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Allart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Shapovalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Prevarskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-8766","authenticated-orcid":false,"given":"V\u2019yacheslav","family":"Lehen\u2019kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2376_CR1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"2376_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670\u2013691 (2017).","journal-title":"Cell"},{"key":"2376_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman, R. E. et al. Bone metastases. Nat. Rev. Dis. Prim. 6, 83 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2376_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/PAP.0000000000000219","volume":"26","author":"M Akhtar","year":"2019","unstructured":"Akhtar, M., Haider, A., Rashid, S. & Al-Nabet, A. D. M. H. Paget\u2019s \u2018seed and soil\u2019 theory of cancer metastasis: an idea whose time has come. Adv. Anat. Pathol. 26, 69\u201374 (2019).","journal-title":"Adv. Anat. Pathol."},{"key":"2376_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571\u2013573 (1889).","journal-title":"Lancet"},{"key":"2376_CR6","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/S0960-9776(19)31133-6","volume":"48","author":"R Coleman","year":"2019","unstructured":"Coleman, R. Clinical benefits of bone targeted agents in early breast cancer. Breast 48, S92\u2013S96 (2019).","journal-title":"Breast"},{"key":"2376_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","volume":"76","author":"R von Moos","year":"2019","unstructured":"von Moos, R. et al. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat. Rev. 76, 57\u201367 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"2376_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","volume":"101","author":"P Cl\u00e9zardin","year":"2021","unstructured":"Cl\u00e9zardin, P. et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol. Rev. 101, 797\u2013855 (2021).","journal-title":"Physiol. Rev."},{"key":"2376_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325\u2013334 (2015).","journal-title":"Eur. Urol."},{"key":"2376_CR10","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"2376_CR11","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243s\u20136249s (2006).","journal-title":"Clin. Cancer Res."},{"key":"2376_CR12","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2376_CR13","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.3390\/jcm10215127","volume":"10","author":"O Fahmy","year":"2021","unstructured":"Fahmy, O. et al. Updates on molecular and biochemical development and progression of prostate cancer. J. Clin. Med. 10, 5127 (2021).","journal-title":"J. Clin. Med."},{"key":"2376_CR14","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi, S. et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J. Clin. Oncol. 34, 1652\u20131659 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2376_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-42","volume":"13","author":"E Joeckel","year":"2014","unstructured":"Joeckel, E. et al. High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol. Cancer 13, 42 (2014).","journal-title":"Mol. Cancer"},{"key":"2376_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/978-3-030-12457-1_22","volume":"1131","author":"BK Puri","year":"2020","unstructured":"Puri, B. K. Calcium signaling and gene expression. Adv. Exp. Med Biol. 1131, 537\u2013545 (2020).","journal-title":"Adv. Exp. Med Biol."},{"key":"2376_CR17","doi-asserted-by":"publisher","first-page":"a035204","DOI":"10.1101\/cshperspect.a035204","volume":"11","author":"SJ Roberts-Thomson","year":"2019","unstructured":"Roberts-Thomson, S. J., Chalmers, S. B. & Monteith, G. R. The calcium-signaling toolkit in cancer: remodeling and targeting. Cold Spring Harb. Perspect. Biol. 11, a035204 (2019).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2376_CR18","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.3390\/cancers13123085","volume":"13","author":"L Bettaieb","year":"2021","unstructured":"Bettaieb, L. et al. Ca2+ signaling and its potential targeting in pancreatic ductal carcinoma. Cancers (Basel) 13, 3085 (2021).","journal-title":"Cancers (Basel)"},{"key":"2376_CR19","doi-asserted-by":"publisher","first-page":"102673","DOI":"10.1016\/j.ceca.2022.102673","volume":"108","author":"O Romito","year":"2022","unstructured":"Romito, O. et al. Calcium signaling: a therapeutic target to overcome resistance to therapies in cancer. Cell Calcium 108, 102673 (2022).","journal-title":"Cell Calcium"},{"key":"2376_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/35077544","volume":"2","author":"DE Clapham","year":"2001","unstructured":"Clapham, D. E., Runnels, L. W. & Str\u00fcbing, C. The TRP ion channel family. Nat. Rev. Neurosci. 2, 387\u2013396 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"2376_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0092-8674(02)00670-0","volume":"108","author":"C Montell","year":"2002","unstructured":"Montell, C., Birnbaumer, L. & Flockerzi, V. The TRP channels, a remarkably functional family. Cell 108, 595\u2013598 (2002).","journal-title":"Cell"},{"key":"2376_CR22","doi-asserted-by":"publisher","first-page":"36546","DOI":"10.1074\/jbc.M404679200","volume":"279","author":"M B\u00f6dding","year":"2004","unstructured":"B\u00f6dding, M. & Flockerzi, V. Ca2+ dependence of the Ca2+-selective TRPV6 channel. J. Biol. Chem. 279, 36546\u201336552 (2004).","journal-title":"J. Biol. Chem."},{"key":"2376_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1152\/physrev.00003.2004","volume":"85","author":"JGJ Hoenderop","year":"2005","unstructured":"Hoenderop, J. G. J., Nilius, B. & Bindels, R. J. M. Calcium absorption across epithelia. Physiol. Rev. 85, 373\u2013422 (2005).","journal-title":"Physiol. Rev."},{"key":"2376_CR24","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1038\/sj.onc.1210545","volume":"26","author":"V Lehen\u2019kyi","year":"2007","unstructured":"Lehen\u2019kyi, V., Flourakis, M., Skryma, R. & Prevarskaya, N. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)\/NFAT-dependent pathways. Oncogene 26, 7380\u20137385 (2007).","journal-title":"Oncogene"},{"key":"2376_CR25","doi-asserted-by":"publisher","first-page":"e20191820","DOI":"10.1084\/jem.20191820","volume":"217","author":"R-Y Ma","year":"2020","unstructured":"Ma, R.-Y. et al. Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. J. Exp. Med. 217, e20191820 (2020).","journal-title":"J. Exp. Med."},{"key":"2376_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1006\/bbrc.2001.4638","volume":"282","author":"JB Peng","year":"2001","unstructured":"Peng, J. B. et al. CaT1 expression correlates with tumor grade in prostate cancer. Biochem. Biophys. Res. Commun. 282, 729\u2013734 (2001).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2376_CR27","doi-asserted-by":"publisher","first-page":"1215645","DOI":"10.3389\/fgene.2023.1215645","volume":"14","author":"C Cordier","year":"2023","unstructured":"Cordier, C., Haustrate, A., Prevarskaya, N. & Lehen\u2019kyi, V. Characterization of the TRPV6 calcium channel-specific phenotype by RNA-seq in castration-resistant human prostate cancer cells. Front. Genet. 14, 1215645 (2023).","journal-title":"Front. Genet."},{"key":"2376_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-06809-0","volume":"15","author":"A Haustrate","year":"2024","unstructured":"Haustrate, A. et al. Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression. Cell Death Dis. 15, 1\u201313 (2024).","journal-title":"Cell Death Dis."},{"key":"2376_CR29","first-page":"3522","volume":"44","author":"JM Kozlowski","year":"1984","unstructured":"Kozlowski, J. M. et al. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 44, 3522\u20133529 (1984).","journal-title":"Cancer Res."},{"key":"2376_CR30","first-page":"163","volume":"15","author":"S Korenchuk","year":"2001","unstructured":"Korenchuk, S. et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163\u2013168 (2001).","journal-title":"In Vivo"},{"key":"2376_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L","volume":"44","author":"GN Thalmann","year":"2000","unstructured":"Thalmann, G. N. et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91\u2013103 (2000).","journal-title":"Prostate"},{"key":"2376_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1023\/B:CLIN.0000006817.25962.87","volume":"20","author":"DE Jenkins","year":"2003","unstructured":"Jenkins, D. E., Yu, S.-F., Hornig, Y. S., Purchio, T. & Contag, P. R. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin. Exp. Metastasis 20, 745\u2013756 (2003).","journal-title":"Clin. Exp. Metastasis"},{"key":"2376_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0165-4608(84)90020-7","volume":"11","author":"Z Gibas","year":"1984","unstructured":"Gibas, Z., Becher, R., Kawinski, E., Horoszewicz, J. & Sandberg, A. A. A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). Cancer Genet. Cytogenet. 11, 399\u2013404 (1984).","journal-title":"Cancer Genet. Cytogenet."},{"key":"2376_CR34","doi-asserted-by":"publisher","first-page":"17930","DOI":"10.1074\/jbc.M111.328286","volume":"287","author":"P Weissgerber","year":"2012","unstructured":"Weissgerber, P. et al. Excision of Trpv6 gene leads to severe defects in epididymal Ca2+ absorption and male fertility much like single D541A pore mutation. J. Biol. Chem. 287, 17930\u201317941 (2012).","journal-title":"J. Biol. Chem."},{"key":"2376_CR35","doi-asserted-by":"publisher","first-page":"E3870","DOI":"10.1073\/pnas.1413409111","volume":"111","author":"M Rapha\u00ebl","year":"2014","unstructured":"Rapha\u00ebl, M. et al. TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc. Natl Acad. Sci. USA 111, E3870\u2013E3879 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2376_CR36","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","volume":"26","author":"W Zhou","year":"2019","unstructured":"Zhou, W., Guo, S., Liu, M., Burow, M. E. & Wang, G. Targeting CXCL12\/CXCR4 axis in tumor immunotherapy. Curr. Med. Chem. 26, 3026\u20133041 (2019).","journal-title":"Curr. Med. Chem."},{"key":"2376_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48818-9","volume":"15","author":"S Abdoul-Azize","year":"2024","unstructured":"Abdoul-Azize, S. et al. Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4\/PLC signaling. Nat. Commun. 15, 4557 (2024).","journal-title":"Nat. Commun."},{"key":"2376_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nm0198-072","volume":"4","author":"GA Donzella","year":"1998","unstructured":"Donzella, G. A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4, 72\u201377 (1998).","journal-title":"Nat. Med."},{"key":"2376_CR39","doi-asserted-by":"publisher","first-page":"e47287","DOI":"10.1371\/journal.pone.0047287","volume":"7","author":"SJ Gros","year":"2012","unstructured":"Gros, S. J. et al. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS ONE 7, e47287 (2012).","journal-title":"PLoS ONE"},{"key":"2376_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100244","volume":"17","author":"G Allocca","year":"2019","unstructured":"Allocca, G. et al. The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo. J. Bone Oncol. 17, 100244 (2019).","journal-title":"J. Bone Oncol."},{"key":"2376_CR41","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood.2021012953","volume":"138","author":"SP Treon","year":"2021","unstructured":"Treon, S. P. et al. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstr\u00f6m macroglobulinemia. Blood 138, 1535\u20131539 (2021).","journal-title":"Blood"},{"key":"2376_CR42","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.18632\/oncotarget.6465","volume":"7","author":"MK Kashyap","year":"2016","unstructured":"Kashyap, M. K. et al. Ulocuplumab (BMS-936564 \/ MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 7, 2809\u20132822 (2016).","journal-title":"Oncotarget"},{"key":"2376_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0987-1","volume":"34","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. Downregulation of TRPM7 suppressed migration and invasion by regulating epithelial-mesenchymal transition in prostate cancer cells. Med. Oncol. 34, 127 (2017).","journal-title":"Med. Oncol."},{"key":"2376_CR44","doi-asserted-by":"publisher","first-page":"e112198","DOI":"10.15252\/embj.2022112198","volume":"42","author":"A Folcher","year":"2023","unstructured":"Folcher, A. et al. NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness. EMBO J. 42, e112198 (2023).","journal-title":"EMBO J."},{"key":"2376_CR45","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/jcp.27371","volume":"234","author":"AI Sagredo","year":"2019","unstructured":"Sagredo, A. I. et al. TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines. J. Cell Physiol. 234, 2037\u20132050 (2019).","journal-title":"J. Cell Physiol."},{"key":"2376_CR46","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1038\/sj.onc.1206895","volume":"22","author":"T Fixemer","year":"2003","unstructured":"Fixemer, T., Wissenbach, U., Flockerzi, V. & Bonkhoff, H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 22, 7858\u20137861 (2003).","journal-title":"Oncogene"},{"key":"2376_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4111\/icu.20200511","volume":"62","author":"DY Kim","year":"2021","unstructured":"Kim, D. Y., Kim, S. H. & Yang, E. K. RNA interference mediated suppression of TRPV6 inhibits the progression of prostate cancer in vitro by modulating cathepsin B and MMP9 expression. Investig. Clin. Urol. 62, 447\u2013454 (2021).","journal-title":"Investig. Clin. Urol."},{"key":"2376_CR48","doi-asserted-by":"publisher","first-page":"146192","DOI":"10.1016\/j.gene.2022.146192","volume":"817","author":"V Khattar","year":"2022","unstructured":"Khattar, V., Wang, L. & Peng, J.-B. Calcium selective channel TRPV6: structure, function, and implications in health and disease. Gene 817, 146192 (2022).","journal-title":"Gene"},{"key":"2376_CR49","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1113\/jphysiol.2011.225862","volume":"590","author":"V Lehen\u2019kyi","year":"2012","unstructured":"Lehen\u2019kyi, V., Rapha\u00ebl, M. & Prevarskaya, N. The role of the TRPV6 channel in cancer. J. Physiol. 590, 1369\u20131376 (2012).","journal-title":"J. Physiol."},{"key":"2376_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/1389450116666150907100715","volume":"17","author":"D Verzella","year":"2016","unstructured":"Verzella, D. et al. Targeting the NF-\u03baB pathway in prostate cancer: a promising therapeutic approach?. Curr. Drug Targets 17, 311\u2013320 (2016).","journal-title":"Curr. Drug Targets"},{"key":"2376_CR51","doi-asserted-by":"publisher","first-page":"e10456","DOI":"10.1371\/journal.pone.0010456","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang, Q. et al. A novel role for Wnt\/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One 5, e10456 (2010).","journal-title":"PLoS One"},{"key":"2376_CR52","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/pros.23512","volume":"78","author":"X Gao","year":"2018","unstructured":"Gao, X. et al. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-\u03baB\/DNMT1 signaling pathway. Prostate 78, 682\u2013690 (2018).","journal-title":"Prostate"},{"key":"2376_CR53","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.1158\/0008-5472.CAN-06-1544","volume":"66","author":"CL Hall","year":"2006","unstructured":"Hall, C. L., Dai, J., van Golen, K. L., Keller, E. T. & Long, M. W. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 66, 8648\u20138654 (2006).","journal-title":"Cancer Res."},{"key":"2376_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2015.06.021","volume":"367","author":"A Katzenwadel","year":"2015","unstructured":"Katzenwadel, A. & Wolf, P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 367, 12\u201317 (2015).","journal-title":"Cancer Lett."},{"key":"2376_CR55","doi-asserted-by":"publisher","first-page":"a030346","DOI":"10.1101\/cshperspect.a030346","volume":"8","author":"M Ittmann","year":"2018","unstructured":"Ittmann, M. Anatomy and histology of the human and murine prostate. Cold Spring Harb. Perspect. Med. 8, a030346 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2376_CR56","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1541-7786.MCR-07-0117","volume":"6","author":"SR Chinni","year":"2008","unstructured":"Chinni, S. R. et al. CXCL12\/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res. 6, 446\u2013457 (2008).","journal-title":"Mol. Cancer Res."},{"key":"2376_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.clbc.2011.05.001","volume":"11","author":"T Ibrahim","year":"2011","unstructured":"Ibrahim, T. et al. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clin. Breast Cancer 11, 369\u2013375 (2011).","journal-title":"Clin. Breast Cancer"},{"key":"2376_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-176","volume":"9","author":"Z-L Xiang","year":"2009","unstructured":"Xiang, Z.-L. et al. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 9, 176 (2009).","journal-title":"BMC Cancer"},{"key":"2376_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ceca.2014.11.005","volume":"57","author":"L Vachel","year":"2015","unstructured":"Vachel, L., Norez, C., Jayle, C., Becq, F. & Vandebrouck, C. The low PLC-\u03b41 expression in cystic fibrosis bronchial epithelial cells induces upregulation of TRPV6 channel activity. Cell Calcium 57, 38\u201348 (2015).","journal-title":"Cell Calcium"},{"key":"2376_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04198-3","volume":"7","author":"X-M Hu","year":"2017","unstructured":"Hu, X.-M. et al. Chemokine receptor CXCR4 regulates CaMKII\/CREB pathway in spinal neurons that underlies cancer-induced bone pain. Sci. Rep. 7, 4005 (2017).","journal-title":"Sci. Rep."},{"key":"2376_CR61","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1038\/oncsis.2017.39","volume":"6","author":"WH Lee","year":"2017","unstructured":"Lee, W. H. et al. TRPV4 plays a role in breast cancer cell migration via Ca2+-dependent activation of AKT and downregulation of E-cadherin cell cortex protein. Oncogenesis 6, e338\u2013e338 (2017).","journal-title":"Oncogenesis"},{"key":"2376_CR62","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/0008-5472.CAN-11-3863","volume":"72","author":"J Middelbeek","year":"2012","unstructured":"Middelbeek, J. et al. TRPM7 is required for breast tumor cell metastasis. Cancer Res. 72, 4250\u20134261 (2012).","journal-title":"Cancer Res."},{"key":"2376_CR63","first-page":"1432","volume":"39","author":"H Song","year":"2018","unstructured":"Song, H. et al. Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer. Oncol. Rep. 39, 1432\u20131440 (2018).","journal-title":"Oncol. Rep."},{"key":"2376_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/19336950.2020.1740506","volume":"14","author":"A Arbabian","year":"2020","unstructured":"Arbabian, A. et al. Mutations in calmodulin-binding domains of TRPV4\/6 channels confer invasive properties to colon adenocarcinoma cells. Channels (Austin) 14, 101\u2013109 (2020).","journal-title":"Channels (Austin)"},{"key":"2376_CR65","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2021.07.017","volume":"519","author":"X Xu","year":"2021","unstructured":"Xu, X., Li, N., Wang, Y., Yu, J. & Mi, J. Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. Cancer Lett. 519, 150\u2013160 (2021).","journal-title":"Cancer Lett."},{"key":"2376_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100611","volume":"47","author":"C Handforth","year":"2024","unstructured":"Handforth, C. et al. The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: a longitudinal observational study (The ANTELOPE Study). J. Bone Oncol. 47, 100611 (2024).","journal-title":"J. Bone Oncol."},{"key":"2376_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100311","volume":"25","author":"JE Brown","year":"2020","unstructured":"Brown, J. E. et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J. Bone Oncol. 25, 100311 (2020).","journal-title":"J. Bone Oncol."},{"key":"2376_CR68","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/0008-5472.CAN-14-2493","volume":"75","author":"JL Sottnik","year":"2015","unstructured":"Sottnik, J. L., Dai, J., Zhang, H., Campbell, B. & Keller, E. T. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 75, 2151\u20132158 (2015).","journal-title":"Cancer Res."},{"key":"2376_CR69","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.joca.2014.11.002","volume":"23","author":"A Sin","year":"2015","unstructured":"Sin, A., Tang, W., Wen, C. Y., Chung, S. K. & Chiu, K. Y. The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis. Osteoarthr. Cartil. 23, 516\u2013524 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"2376_CR70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/pros.23270","volume":"77","author":"\u00c1 Gonz\u00e1lez","year":"2017","unstructured":"Gonz\u00e1lez, \u00c1 et al. Distinct osteomimetic response of androgen-dependent and independent human prostate cancer cells to mechanical action of fluid flow: prometastatic implications. Prostate 77, 321\u2013333 (2017).","journal-title":"Prostate"},{"key":"2376_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U","volume":"39","author":"KS Koeneman","year":"1999","unstructured":"Koeneman, K. S., Yeung, F. & Chung, L. W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39, 246\u2013261 (1999).","journal-title":"Prostate"},{"key":"2376_CR72","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/cancers12051071","volume":"12","author":"JA Ardura","year":"2020","unstructured":"Ardura, J. A., \u00c1lvarez-Carri\u00f3n, L., Guti\u00e9rrez-Rojas, I. & Alonso, V. Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms. Cancers 12, 1071 (2020).","journal-title":"Cancers"},{"key":"2376_CR73","doi-asserted-by":"publisher","first-page":"445","DOI":"10.37349\/etat.2022.00094","volume":"3","author":"T Xie","year":"2022","unstructured":"Xie, T. et al. Roles of calcium signaling in cancer metastasis to bone. Explor. Target Antitumor Ther. 3, 445\u2013462 (2022).","journal-title":"Explor. Target Antitumor Ther."},{"key":"2376_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-020-00105-1","volume":"8","author":"M Wang","year":"2020","unstructured":"Wang, M., Xia, F., Wei, Y. & Wei, X. Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res. 8, 1\u201320 (2020).","journal-title":"Bone Res."},{"key":"2376_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164918","volume":"133","author":"DH McDermott","year":"2023","unstructured":"McDermott, D. H. et al. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. J. Clin. Investig. 133, e164918 (2023).","journal-title":"J. Clin. Investig."},{"key":"2376_CR76","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s12185-021-03109-7","volume":"113","author":"T Mori","year":"2021","unstructured":"Mori, T. et al. Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation. Int. J. Hematol. 113, 877\u2013883 (2021).","journal-title":"Int. J. Hematol."},{"key":"2376_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100416","volume":"33","author":"B Cadieux","year":"2022","unstructured":"Cadieux, B. et al. Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval. J. Bone Oncol. 33, 100416 (2022).","journal-title":"J. Bone Oncol."},{"key":"2376_CR78","doi-asserted-by":"publisher","first-page":"1121878","DOI":"10.3389\/fimmu.2023.1121878","volume":"14","author":"TE K\u00e4hk\u00f6nen","year":"2023","unstructured":"K\u00e4hk\u00f6nen, T. E., Halleen, J. M., MacRitchie, G., Andersson, R. M. & Bernoulli, J. Insights into immuno-oncology drug development landscape with focus on bone metastasis. Front. Immunol. 14, 1121878 (2023).","journal-title":"Front. Immunol."},{"key":"2376_CR79","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/ijms24010419","volume":"24","author":"A Haustrate","year":"2022","unstructured":"Haustrate, A. et al. A novel Anti-TRPV6 antibody and its application in cancer diagnosis in vitro. Int. J. Mol. Sci. 24, 419 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2376_CR80","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Min. Res. 25, 1468\u20131486 (2010).","journal-title":"J. Bone Min. Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02376-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T23:02:30Z","timestamp":1757026950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02376-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors (A.H., N.P., and V.L.) have a patent application, EP21306238, related to the use of the monoclonal antibody anti-TRPV6. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}